🇺🇸 FDA
Patent

US 8785373

Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment

granted A61KA61K2039/505A61K38/1709

Quick answer

US patent 8785373 (Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
Grant date
Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K2039/505, A61K38/1709, A61P, A61P13/08